



FREEDOM
— FROM —
PAIN



FREEDOM
— TO —
LIVE



Althea™

Althea Group Holdings Limited (ASX:AGH)
PAC Partners Hong Kong Conference | June 2019



ESTABLISHED

**Australian licensed producer, supplier and exporter
of pharmaceutical grade medicinal cannabis**

EDUCATION


**Providing medicinal cannabis education
access and management services**
Supporting eligible patients and healthcare professionals
in navigating medicinal cannabis treatment pathways

EXPANSION

Operating in highly regulated medicinal cannabis markets
Currently in Australia and the United Kingdom
Expansion opportunities in emerging markets: Europe & Asia

ACCESS MADE SIMPLE

Althea Group Holdings Limited (ASX:AGH)



Althea Concierge

An online platform for
patients, doctors and
pharmacies to manage
their medicinal
cannabis needs in
Australia

Althea Group Holdings Limited (ASX:AGH)

Key Market Statistics | Listed on ASX: 21 September 2018

Key Market Statistics¹

ASX code	AGH
Listing price (Date of listing)	\$0.20
Share price (current price)	\$0.670
Market capitalisation	\$136.22m
Shares on issue	203.31m
GISC clarification	Pharmaceutical, Biotechnology & Life Sciences

¹As at 11 June 2019

Share Price Performance | September 2018 - June 2019



Top Shareholders

Joshua Fegan (CEO)	28%
Aphria Inc. (NYSE:APHA)	25%

“Althea aims to supply pharmaceutical grade medicinal cannabis products to help improve the lives of patients suffering from debilitating conditions.”



Althea Group Holdings Limited (ASX:AGH)

Experienced & Relevant Leadership Team



Andrew Newbold
Chairman & Independent
Non-Executive

- Extensive experience as director of numerous private companies and not-for-profit organisations
- 20 years' experience as a commercial lawyer and has played an integral role in the development of various businesses.



Joshua Fegan
Chief Executive Officer
& Founder

- Founder of Althea Group with extensive experience in business building, sales and marketing
- Proven business and strategy skills and previously held numerous senior management roles at national value-based retailer, Strathfield Group



Penny Dobson
Independent Non-Executive
Director

- Accomplished business executive in healthcare industry and trained pharmacist in New Zealand, three decades at global pharma Merck & Co, in a variety of commercial roles
- Currently Deputy Chair of the Australian Nuclear Science and Technology Organisation Board, and a non-executive director at Invetiv Pty Ltd



Alan Boyd
Independent Non-Executive
Director

- Chief Financial Officer and Company Secretary of Ridley Corporation, an ASX-listed provider of high-performance animal nutrition solutions
- Alan has occupied the same position with listed biotechnology companies Avexa Limited and Zenyth Therapeutics Limited

Althea Group Holdings: Licenses

Full Suite Of Licences from The Office of Drug Control (ODC)



Althea has been granted the full suite of licenses for pharmaceutical grade medicinal cannabis from The Office of Drug Control (ODC) in Australia

Althea: Producing, Cultivating, Manufacturing

Althea has the right to grow and manufacture medicinal cannabis products

Althea: Supplying, Importing

Althea has the right to import medicinal cannabis products for distribution to patients in Australia

Althea: Exporting

Althea has the ability to export Althea medicinal cannabis products into other jurisdictions



Australian Government

**Department of Health
Office of Drug Control**

AGRICULTURE VICTORIA



Althea is one of few companies that has been granted the full suite of licenses for pharmaceutical grade medicinal cannabis in Australia along with a Hemp Cultivation Licence granted by Agriculture Victoria



Althea Group Holdings: Products

Pharmaceutical Grade Medicinal Cannabis Products



Althea strives to ensure patients are supplied with pharmaceutical grade, full spectrum, medicinal cannabis products

The safety, consistency and quality of Althea medicinal cannabis is ensured by Seed-to-Sale Certification – a strict quality management programme consisting of 509 steps throughout the cultivation and manufacturing of products.

Althea's medicinal cannabis products are currently greenhouse grown and manufactured by Althea 25% shareholder, Canadian cannabis company Aphria Inc. (NYSE:APHA)



Althea Group Holdings: Education

Providing Medicinal Cannabis Education Access & Management Services

Althea Concierge is supported in the field by our team of Medical Science Liaisons who work face-to-face with healthcare professionals



Althea Concierge is a free online service for patients, healthcare professionals and pharmacists, and is designed to simplify access to medicinal cannabis, and patient management.

Althea Concierge has been created to be compatible with the regulations governing access to medicinal cannabis specific to your country.

How can I find a doctor to prescribe medicinal cannabis for my condition?
Patients must first consult their specialist or GP about medicinal cannabis – depending on the patient's state or country they may need a referral to a specialist to obtain a prescription. Althea Concierge can assist patients in finding a local doctor who is familiar with prescribing medicinal cannabis.



Althea Group Holdings: Education

Providing Medicinal Cannabis Education Access & Management Services



Althea Concierge launched September 2018:

- Creating a growing channel that is proactively engaged with Althea, its products and educational content
- Increased user uptake will be a focus in 2H 2019, predominantly through dedicated marketing activity and promotion through the MEDIC HCP Education Platform
- Althea Concierge is a complimentary service. Althea believes patients have the right to talk to 'everyday' doctors about medicinal cannabis
- Althea Concierge UK launched May 2019

Simplifying access to medicinal cannabis for patients, HCPS and pharmacists
(Australian example)

Patients

- Find doctors and information on accessing medicinal cannabis

Healthcare Professionals (HCP)

- Complete SAS B applications in as little as five minutes and access patient treatment plans

Pharmacists

- Find dispensing and product information for Althea Medicinal Cannabis
- Althea Medical Science Liaisons**
- Supporting HCP's in the field

Simplifying Access To Medicinal Cannabis For Patients, Health Care Professionals & Pharmacists

“Althea Concierge has been a godsend for doctors in Australia who otherwise would not have the time or capacity to submit applications on behalf of patients, which is required before they can prescribe medicinal cannabis.

We have feedback from prescribing doctors that they are able to complete applications with Althea Concierge *in fewer than five minutes*, a far cry from the alternative application methods which can take doctors hours.”

Althea Chief Executive Officer & Founder, Joshua Fegan



Althea Group Holdings: Education

Providing Medicinal Cannabis Education Access & Management Services



MEDIC | HCP Education Platform

- MEDIC is an online portal offering free, evidence-based education and resources on:
 - The endocannabinoid system
 - Safety and clinical considerations
 - Management of chronic non-cancer pain
 - Mental health, CINV and other conditions
- Accredited by The Royal Australian College of General Practitioners (RACGP)

Althea has partnered with Drug Science to further education on medicinal cannabis and improve patient access

- Drug Science is the United Kingdom's only completely independent scientific committee on drugs
- Drug Science will use Althea's recently launched learning portal MEDIC to educate healthcare professionals about medicinal cannabis
- Drug Science aims to have MEDIC accredited by UK organisations including the Royal College of General Practitioners to enable healthcare professionals to receive continuing professional development points for completing courses




Medicinal Cannabis: Treatment

Increasing Evidence Of Effectiveness

Medicinal cannabis products are accepted as being effective in the treatment of certain medical conditions including chronic pain, sleep & mood disorders, mental health, nausea, vomiting, epilepsy, and pain & spasticity caused by multiple sclerosis.

- The main active pharmaceutical ingredients in medicinal cannabis products are cannabinoids, including but not limited to THC (tetrahydrocannabinol) and CBD (cannabidiol).
- The regulations for accessing medicinal cannabis differ from country to country.




Medicinal Cannabis: History & Outlook in Australia

Increasing Usage & Growing Industry



For doctors, the Therapeutic Goods Administration's (TGA) special access scheme requires an application form to be filled out for each patient, detailing their medical history and justifying why medicinal cannabis is an appropriate treatment



Therapeutic Goods Administration (TGA) TGA SAS B Monthly Application Approvals (Cumulative)

Cannabis on track to become a \$1.2 billion industry over the next 10 years
- Prohibition Partners

Medicinal cannabis patient numbers are expected surpass the 120,000 mark in the next four years as education programs aimed at getting doctors across the country familiar with prescribing the drug take off
- BuddingTech


The patient market in Australia expected to grow at around 9% per month over the coming year, resulting in around 15,000 – 20,000 new patients entering the market in 2019
- FreshLeaf Analytics

Medicinal Cannabis: Althea in Australia


Accelerating Patient & Prescriber Growth



Althea's Accelerating Patient Growth in Australia



Althea's Accelerating Doctor Growth in Australia



Case Studies: Althea in Australia

Real Patients Using Medicinal Cannabis With Real Results



Patient: 8 year-old boy | Indication: Autism and ADHD

- Patient had seen multiple Psychiatrists, Neurologists, Paediatricians in both private and public hospital clinics with no success in treating his severe violent behavioural outbursts and autism symptoms.
- GP successfully prescribed Althea medicinal cannabis product.
- After two weeks of taking the product, the patient's symptoms improved with no evidence of side effects.

Patient: 32-year old male | Indication: Chronic Non-Cancer Pain

- Patient suffered spinal injury which left him with refractory sciatica pain and lower back pain which could not be effectively managed using traditional pain management/anti-inflammatory products and anti-depressants.
- The condition further led to anxiety.
- Since taking Althea medicinal cannabis products for pain management and as a sleep aid, the patient's quality of life and overall mood have significantly improved.
- Patient is taking two Althea medicinal cannabis products. One manages pain during the day while the other, taken at night, helps sleep without waking with breakthrough pain.



Medicinal Cannabis: Althea in the United Kingdom

Expanding Operations To Accommodate Patient Access



Althea's Opportunity: United Kingdom

The United Kingdom's highly regulated framework for prescribing, supplying and possessing medicinal cannabis products is very similar to that of Australia. With a population of 66 million people, research by Prohibition Partners suggests that medical cannabis can treat up to 2.9 million patients in the United Kingdom

Althea's Operations: United Kingdom

- Althea announced it will be one of the first to enter the UK Medicinal Cannabis market in February 2019
- Operations are now underway in the UK, with 12 personnel headquartered in London
- UK doctors are already assessing patients for the use of Althea medicinal cannabis, with products able to be supplied on a named patient basis upon prescription
- Althea UK products have been approved by Ministry of Health (MoH) and Home Office bulk import permit expected imminently

Althea is one of the first medicinal cannabis companies to enter the UK market. Althea UK has engaged a dozen representatives in the UK, with its head office in Camberley, 30 miles southwest of London.

The United Kingdom will create a second significant distribution channel for Althea's Australian grown and manufactured products once available – projected for 2020

Althea is able to export medicinal cannabis products to the United Kingdom on a named patient basis

Medicinal Cannabis: Althea in the United Kingdom

Expanding Operations To Accommodate Patient Access



ASX Announcement | 31 May 2019

Althea Launches UK Concierge Platform

Commences First Assessments of Patients in the UK

Investment Highlights

- Althea Concierge UK launches successfully with doctors already commencing their first assessments of patients for Althea medical cannabis products
- Althea Concierge UK streamlines the prescription process and facilitates patient referrals from primary care doctors to Althea UK specialist prescribers
- Althea and Drug Science joint educational meetings to be held in June are oversubscribed, with nearly 300 healthcare professionals registered to attend
- Althea sponsored and participated in the recent Improving Outcomes in the Treatment of Opioid Dependence (IOTOD) Conference in Germany

"The launch of Althea Concierge UK and progression of our partnerships with two leading UK scientific committees are key developments for our UK expansion."

- Chief Executive Officer & Founder, Joshua Fegan

Althea's International Strategic Growth Initiatives

Export & Emerging Market Opportunities



- **AUSTRALIA:** Export of medicinal cannabis products from Australia is permitted under the Narcotic Drugs Amendment (Cannabis) Regulations 2018
- Export enhances the viability of the Australian medicinal cannabis industry as Australian licensed producers can now access overseas markets where importation is legal



- **UNITED KINGDOM:** Althea expects that the UK will create a second significant distribution channel for Althea's Australian-grown and manufactured products



- **FRANCE:** France has a population 67 million and is expected to have legalisation in the first half of 2020 and is a logical next step in Althea's European strategy



- **SOUTH KOREA:** Althea is currently exploring opportunities in South Korea which has a population of 51 million and where medicinal cannabis is being legalised



- **UNITED STATES OF AMERICA:** Althea will continue to monitor the status of other emerging markets, including the USA – where federal legislation of medicinal cannabis would likely be highly regulated



Althea Group Holdings Limited (ASX:AGH)

ACCESS MADE SIMPLE

www.althea.life

Althea Group Holdings Limited

Joshua Fegan, CEO & Managing Director

1300 70 20 20 | contact@althea.com.au

Investors: PAC Partners Securities

03 8633 9834 | enquiries@pacpartners.com.au

Media: The Capital Network

Julia Maguire, Executive Director

0419 815 386 | julia@thecapitalnetwork.com.au

Althea Group Holdings Limited

ACN 626 966 943

Registered office: Suite 2, Level 37

360 Elizabeth Street, Melbourne

Victoria, Australia 3000



Althea Group Holdings

Legal Disclaimer

Althea Group Holdings Limited ACN 626 966 943 (**Company**) has prepared this presentation (**Presentation**) dated 12 June 2019 to provide current and prospective investors in the Company with an update in relation to the Company, its subsidiaries and their activities. The information in this Presentation discusses the Company's operations and product range. It is not intended as a promotion of the Company's products. This Presentation contains summary information about the Company, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). This Presentation has not been and will not be filed with or approved by any regulatory authority in Australia, including the Australian Securities and Investments Commission (**ASIC**), or any other jurisdiction. The historical information in this Presentation is, or is based upon, information that has been lodged with the Australian Securities Exchange (**ASX**) and released on the ASX Market Announcements Platform. This Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements which are available at www.asx.com.au (Company Code: AGH) or www.althea.com.au.

This Presentation does not constitute and should not be considered as an offer, invitation or recommendation to subscribe for or purchase any security in the Company in any jurisdiction. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been, and will not be, registered under the U.S. Securities Act of 1933 (**Securities Act**) or the securities laws of any state or other jurisdiction in the United States and may not be offered or sold in the United States without registration except in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and any other applicable U.S. State securities laws. Neither this Presentation nor anything contained in it forms the basis of any contract or commitment and no agreement to subscribe for securities will be entered into on the basis of this Presentation. This Presentation does not take into account any recipient's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of any security in the Company.

To the maximum extent permitted by law, no representation, warranty or undertaking (express or implied) is made, and no responsibility is accepted by the Company or any of its affiliates, related bodies corporate, partners, shareholders, directors, officers, employees, representatives, consultants or advisers or any other person (Parties) as to the adequacy, accuracy, completeness or reasonableness of any statement or any of the information contained in or referred to in this Presentation or as to any other related matter. To the maximum extent permitted by law, none of the Parties takes any responsibility for any loss or damage suffered as a result of any inadequacy, incompleteness or inaccuracy in any such statement or information. To the maximum extent permitted by law, the Parties do not accept any liability to any person for any direct, indirect or consequential loss or damage arising from the use of this material. This Presentation is not a recommendation by any of the Parties that any recipient invest in the Company.

Past performance information provided in this presentation may not be a reliable indication of future performance. This Presentation contains certain forward-looking statements and comments about future events. Forward-looking statements involve known and unknown risks, significant uncertainties, assumptions, contingencies, and other factors, many of which are outside the control of the Company, are subject to change without notice, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and which may cause the actual results or performance of the Company to be materially different from any results or performance expressed or implied by such forward-looking statements. Such forward-looking statements speak only as of the date of this Presentation. Forward looking statements should not be relied on as an indication or guarantee of future performance. No representation, warranty or undertaking is made that any projection, forecast, assumption or estimate contained in this Presentation should or will be achieved. Recipients must conduct their own independent investigation, evaluation and analysis of the matters and data set out in this Presentation, and rely entirely on such investigation and analysis. Recipients must form their own opinion as to whether or not to enter into any arrangements with the Company. The distribution of this document in jurisdictions outside Australia may be restricted by law. If you are outside Australia, you may not be a person to whom an offer of securities in the Company may lawfully be made under the applicable laws in the jurisdiction in which you are situated without registration, lodgment or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. Any such restrictions should be observed. By accepting this Presentation, you agree to be bound by the foregoing limitations and conditions.